Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Parallel Group,Controlled Study to Compare the Immunogenicity and Safety of MSB11455 and Neulasta® in Healthy Adult Subjects

NCT03251339 is registered in ClinicalTrials.gov with Fresenius Kabi SwissBioSim GmbH as lead sponsor.

NCT NCT03251339
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03251339 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Parallel Group,Controlled Study to Compare the Immunogenicity and Safety of MSB11455 and Neulasta® in Healthy Adult Subjects
Lead sponsor
Fresenius Kabi SwissBioSim GmbH
Phase
Phase 1
Overall status
Completed
Start date
August 21, 2017
Completion date
September 22, 2018
Enrollment
336 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy